John T. Treace

John T. Treace, listed as chief executive, appears in our data through filings on Treace Medical Concepts, Inc. shares, published by SEC (Form 4). We count 31 filings; the first trade dates from 20 October 2021 and the latest from 24 August 2026.

Both buying and selling appear: 16 purchases worth €5.3M, against 6 sales worth €2.6M. Netting one side against the other leaves €2.7M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 9 share grants. In 2026 alone, the filings show 4 purchases and no sales.

A typical purchase (the median) is worth €282k. Measured against the company's value, the median purchase equals 0.024% of market capitalisation, across 4 purchases where it is known. 6 out of 16 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 24 August 2026: an open-market purchase of €152k, in Treace Medical Concepts, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.